JP2000510471A - 分散性高分子組成物並びにそれらの調製及び使用のための方法 - Google Patents

分散性高分子組成物並びにそれらの調製及び使用のための方法

Info

Publication number: JP2000510471A
Authority: JP; Japan
Prior art keywords: particles; drying; weight; powder; droplets
Prior art date: 1996-05-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

JP09540191A

Other languages

English (en)

Japanese (ja)

Other versions

JP2000510471A5 (2

Inventor

エム．プラッツ，ロバート

ケー．ブレワー，トーマス

ボードマン，ターエンス

Original Assignee

インヘイルセラピューティックシステムズ

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-08

Filing date

1997-05-07

Publication date

2000-08-15

1997-05-07 Application filed by インヘイルセラピューティックシステムズ filed Critical インヘイルセラピューティックシステムズ

2000-08-15 Publication of JP2000510471A publication Critical patent/JP2000510471A/ja

2004-12-09 Publication of JP2000510471A5 publication Critical patent/JP2000510471A5/ja

Status Withdrawn legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 80
239000000203 mixture Substances 0.000 title claims abstract description 59
229920000642 polymer Polymers 0.000 title claims abstract description 28
238000002360 preparation method Methods 0.000 title description 8
239000002245 particle Substances 0.000 claims abstract description 120
239000000843 powder Substances 0.000 claims abstract description 88
238000001035 drying Methods 0.000 claims abstract description 43
229920001222 biopolymer Polymers 0.000 claims abstract description 23
239000007788 liquid Substances 0.000 claims description 38
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 26
210000004072 lung Anatomy 0.000 claims description 21
239000002609 medium Substances 0.000 claims description 17
102000004169 proteins and genes Human genes 0.000 claims description 16
108090000623 proteins and genes Proteins 0.000 claims description 16
239000007787 solid Substances 0.000 claims description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
102000004877 Insulin Human genes 0.000 claims description 13
108090001061 Insulin Proteins 0.000 claims description 13
229940125396 insulin Drugs 0.000 claims description 13
239000012530 fluid Substances 0.000 claims description 12
239000006185 dispersion Substances 0.000 claims description 10
229920002521 macromolecule Polymers 0.000 claims description 10
150000004676 glycans Chemical class 0.000 claims description 8
229920001282 polysaccharide Polymers 0.000 claims description 8
239000005017 polysaccharide Substances 0.000 claims description 8
239000000835 fiber Substances 0.000 claims description 7
238000004806 packaging method and process Methods 0.000 claims description 7
239000000546 pharmaceutical excipient Substances 0.000 claims description 7
102000039446 nucleic acids Human genes 0.000 claims description 6
108020004707 nucleic acids Proteins 0.000 claims description 6
150000007523 nucleic acids Chemical class 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 5
229910052751 metal Inorganic materials 0.000 claims description 5
239000002184 metal Substances 0.000 claims description 5
230000035699 permeability Effects 0.000 claims description 3
238000011144 upstream manufacturing Methods 0.000 claims description 3
239000004744 fabric Substances 0.000 claims description 2
239000012736 aqueous medium Substances 0.000 claims 1
239000002131 composite material Substances 0.000 claims 1
238000012384 transportation and delivery Methods 0.000 abstract description 27
230000002685 pulmonary effect Effects 0.000 abstract description 15
238000000889 atomisation Methods 0.000 abstract description 14
230000001225 therapeutic effect Effects 0.000 abstract description 5
239000006193 liquid solution Substances 0.000 abstract 1
239000007789 gas Substances 0.000 description 45
239000003814 drug Substances 0.000 description 28
229940079593 drug Drugs 0.000 description 22
239000000243 solution Substances 0.000 description 22
239000007921 spray Substances 0.000 description 18
238000001694 spray drying Methods 0.000 description 18
238000000926 separation method Methods 0.000 description 13
235000018102 proteins Nutrition 0.000 description 11
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
238000009826 distribution Methods 0.000 description 10
239000006199 nebulizer Substances 0.000 description 10
230000008569 process Effects 0.000 description 10
239000000443 aerosol Substances 0.000 description 9
239000000463 material Substances 0.000 description 7
229920001184 polypeptide Polymers 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
239000000047 product Substances 0.000 description 6
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
239000004471 Glycine Substances 0.000 description 5
229930195725 Mannitol Natural products 0.000 description 5
150000001413 amino acids Chemical group 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000000594 mannitol Substances 0.000 description 5
235000010355 mannitol Nutrition 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
230000035515 penetration Effects 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
239000001509 sodium citrate Substances 0.000 description 5
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
235000014633 carbohydrates Nutrition 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000003623 enhancer Substances 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
102000008100 Human Serum Albumin Human genes 0.000 description 3
108091006905 Human Serum Albumin Proteins 0.000 description 3
230000002411 adverse Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000004087 circulation Effects 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
238000001816 cooling Methods 0.000 description 3
238000010586 diagram Methods 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
230000002572 peristaltic effect Effects 0.000 description 3
238000005498 polishing Methods 0.000 description 3
229920001296 polysiloxane Polymers 0.000 description 3
238000012383 pulmonary drug delivery Methods 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
238000004513 sizing Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000011882 ultra-fine particle Substances 0.000 description 3
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
239000005913 Maltodextrin Substances 0.000 description 2
229920002774 Maltodextrin Polymers 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
102000003982 Parathyroid hormone Human genes 0.000 description 2
108090000445 Parathyroid hormone Proteins 0.000 description 2
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000000654 additive Substances 0.000 description 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000004067 bulking agent Substances 0.000 description 2
239000012159 carrier gas Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000013461 design Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
239000010419 fine particle Substances 0.000 description 2
239000011888 foil Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000002650 laminated plastic Substances 0.000 description 2
229940035034 maltodextrin Drugs 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229960002259 nedocromil sodium Drugs 0.000 description 2
239000000199 parathyroid hormone Substances 0.000 description 2
229960001319 parathyroid hormone Drugs 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
239000002002 slurry Substances 0.000 description 2
238000005507 spraying Methods 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
101001011741 Bos taurus Insulin Proteins 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010007979 Glycocholic Acid Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000976075 Homo sapiens Insulin Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000019223 Interleukin-1 receptor Human genes 0.000 description 1
108050006617 Interleukin-1 receptor Proteins 0.000 description 1
240000007049 Juglans regia Species 0.000 description 1
235000009496 Juglans regia Nutrition 0.000 description 1
LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
229920002884 Laureth 4 Polymers 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
102000015731 Peptide Hormones Human genes 0.000 description 1
108010038988 Peptide Hormones Proteins 0.000 description 1
230000018199 S phase Effects 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000012993 chemical processing Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000000498 cooling water Substances 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
238000000280 densification Methods 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
229940112141 dry powder inhaler Drugs 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000009477 glass transition Effects 0.000 description 1
RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
230000005484 gravity Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
230000001788 irregular Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229940062711 laureth-9 Drugs 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000003055 low molecular weight heparin Substances 0.000 description 1
229940127215 low-molecular weight heparin Drugs 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
238000002663 nebulization Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000004482 other powder Substances 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000035485 pulse pressure Effects 0.000 description 1
238000001812 pycnometry Methods 0.000 description 1
238000000197 pyrolysis Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000004626 scanning electron microscopy Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000010378 sodium ascorbate Nutrition 0.000 description 1
PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
229960005055 sodium ascorbate Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000005211 surface analysis Methods 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000010977 unit operation Methods 0.000 description 1
229940070384 ventolin Drugs 0.000 description 1
235000020234 walnut Nutrition 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Zoology (AREA)
Otolaryngology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Glanulating (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

JP09540191A 1996-05-08 1997-05-07 分散性高分子組成物並びにそれらの調製及び使用のための方法 Withdrawn JP2000510471A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/644,681 US6051256A (en)	1994-03-07	1996-05-08	Dispersible macromolecule compositions and methods for their preparation and use
US08/644,681		1996-05-08
PCT/US1997/007779 WO1997041833A1 (en)	1996-05-08	1997-05-07	Dispersible macromolecule compositions and methods for their preparation and use

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2009099209A Division JP2009191071A (ja)	1996-05-08	2009-04-15	分散性高分子組成物並びにそれらの調製及び使用のための方法

Publications (2)

Publication Number	Publication Date
JP2000510471A true JP2000510471A (ja)	2000-08-15
JP2000510471A5 JP2000510471A5 (2)	2004-12-09

Family

ID=24585923

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP09540191A Withdrawn JP2000510471A (ja)	1996-05-08	1997-05-07	分散性高分子組成物並びにそれらの調製及び使用のための方法
JP2009099209A Pending JP2009191071A (ja)	1996-05-08	2009-04-15	分散性高分子組成物並びにそれらの調製及び使用のための方法

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2009099209A Pending JP2009191071A (ja)	1996-05-08	2009-04-15	分散性高分子組成物並びにそれらの調製及び使用のための方法

Country Status (29)

Country	Link
US (5)	US6051256A (2)
EP (1)	EP0948317A4 (2)
JP (2)	JP2000510471A (2)
CN (1)	CN1138531C (2)
AP (1)	AP987A (2)
AU (1)	AU730059B2 (2)
BG (1)	BG64113B1 (2)
BR (1)	BR9709057A (2)
CA (1)	CA2253393C (2)
CZ (1)	CZ295644B6 (2)
EA (1)	EA000956B1 (2)
EE (1)	EE03591B1 (2)
GE (1)	GEP20012345B (2)
IL (1)	IL126754A (2)
IS (1)	IS4879A (2)
LT (1)	LT4553B (2)
LV (1)	LV12231B (2)
NO (1)	NO985196L (2)
NZ (1)	NZ332480A (2)
OA (1)	OA10914A (2)
PL (1)	PL190732B1 (2)
RO (1)	RO118523B1 (2)
SI (1)	SI9720031A (2)
SK (1)	SK285400B6 (2)
TR (1)	TR199802247T2 (2)
TW (1)	TW550089B (2)
UA (1)	UA65538C2 (2)
WO (1)	WO1997041833A1 (2)
YU (1)	YU49206B (2)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006512102A (ja) *	2002-04-11	2006-04-13	メディミューン・ヴァクシンズ・インコーポレーテッド	噴霧乾燥による生物活性材料の防腐
JP2007522246A (ja) *	2004-02-12	2007-08-09	ネクターセラピューティクス	インターロイキン−１３拮抗剤粉末剤、スプレードライ粒子、及び方法
JP2007536313A (ja) *	2004-05-10	2007-12-13	ベーリンガーインゲルハイムファルマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト	少なくとも１種の１，４ｏ−結合型サッカロース誘導体を含有する噴霧乾燥粉末及びその製造方法
JP2007536315A (ja) *	2004-05-10	2007-12-13	ベーリンガーインゲルハイムファルマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト	新規なオリゴ糖混合物を含有する粉末及びその製造方法
JP2011006444A (ja) *	2002-12-17	2011-01-13	Medimmune Llc	生物活性材料の高圧噴霧乾燥
JP4808970B2 (ja) *	2002-12-30	2011-11-02	ネクターセラピューティクス	噴霧乾燥システム
JP4837892B2 (ja) *	2001-11-01	2011-12-14	ネクターセラピューティクス	粉末バッチを製造する方法

Families Citing this family (362)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6673335B1 (en) *	1992-07-08	2004-01-06	Nektar Therapeutics	Compositions and methods for the pulmonary delivery of aerosolized medicaments
ES2179831T3 (es) *	1992-09-29	2003-02-01	Inhale Therapeutic Syst	Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana.
US7448375B2 (en) *	1993-01-29	2008-11-11	Aradigm Corporation	Method of treating diabetes mellitus in a patient
US6024090A (en) *	1993-01-29	2000-02-15	Aradigm Corporation	Method of treating a diabetic patient by aerosolized administration of insulin lispro
US20010003739A1 (en) *	1993-06-24	2001-06-14	Astrazeneca Ab	Systemic administration of a therapeutic preparation
US6632456B1 (en)	1993-06-24	2003-10-14	Astrazeneca Ab	Compositions for inhalation
US5830853A (en)	1994-06-23	1998-11-03	Astra Aktiebolag	Systemic administration of a therapeutic preparation
TW402506B (en)	1993-06-24	2000-08-21	Astra Ab	Therapeutic preparation for inhalation
US6794357B1 (en) *	1993-06-24	2004-09-21	Astrazeneca Ab	Compositions for inhalation
US6051256A (en) *	1994-03-07	2000-04-18	Inhale Therapeutic Systems	Dispersible macromolecule compositions and methods for their preparation and use
NZ281112A (en) *	1994-03-07	1998-04-27	Inhale Therapeutic Syst	Powdered insulin delivered as an aerosol
ES2245780T3 (es) *	1994-05-18	2006-01-16	Nektar Therapeutics	Metodos y composiciones para la formulacion de interferones como un polvo seco.
US6165976A (en)	1994-06-23	2000-12-26	Astra Aktiebolag	Therapeutic preparation for inhalation
US6290991B1 (en) *	1994-12-02	2001-09-18	Quandrant Holdings Cambridge Limited	Solid dose delivery vehicle and methods of making same
US6524557B1 (en)	1994-12-22	2003-02-25	Astrazeneca Ab	Aerosol formulations of peptides and proteins
EP0806940B1 (en)	1994-12-22	2003-04-09	AstraZeneca AB	Aerosol drug formulations
CA2206657C (en)	1994-12-22	2009-05-19	Astra Aktiebolag	Therapeutic preparation for inhalation containing parathyroid hormone, pth
US6019968A (en) *	1995-04-14	2000-02-01	Inhale Therapeutic Systems, Inc.	Dispersible antibody compositions and methods for their preparation and use
US6165463A (en)	1997-10-16	2000-12-26	Inhale Therapeutic Systems, Inc.	Dispersible antibody compositions and methods for their preparation and use
US6309671B1 (en)	1995-04-14	2001-10-30	Inhale Therapeutic Systems	Stable glassy state powder formulations
US6258341B1 (en)	1995-04-14	2001-07-10	Inhale Therapeutic Systems, Inc.	Stable glassy state powder formulations
US6428771B1 (en) *	1995-05-15	2002-08-06	Pharmaceutical Discovery Corporation	Method for drug delivery to the pulmonary system
GB9515182D0 (en) *	1995-07-24	1995-09-20	Co Ordinated Drug Dev	Improvements in and relating to powders for use in dry powder inhalers
UA59358C2 (uk)	1996-01-24	2003-09-15	Бик Гулден Ломберг Хеміше Фабрік Гмбх	Спосіб приготування порошкоподібного пульмонологічного порошкоподібного препарату та препарат, одержаний в такий спосіб
US6254854B1 (en)	1996-05-24	2001-07-03	The Penn Research Foundation	Porous particles for deep lung delivery
US6503480B1 (en) *	1997-05-23	2003-01-07	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
US20030203036A1 (en) *	2000-03-17	2003-10-30	Gordon Marc S.	Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US20030035778A1 (en) *	1997-07-14	2003-02-20	Robert Platz	Methods and compositions for the dry powder formulation of interferon
NZ502358A (en) *	1997-07-18	2002-11-26	Infimed Therapeutics Inc	Hydrogel composition comprising a biologically active substance combined with a macromer
US6946117B1 (en)	1997-09-29	2005-09-20	Nektar Therapeutics	Stabilized preparations for use in nebulizers
US20060165606A1 (en)	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US6433040B1 (en)	1997-09-29	2002-08-13	Inhale Therapeutic Systems, Inc.	Stabilized bioactive preparations and methods of use
US6309623B1 (en) *	1997-09-29	2001-10-30	Inhale Therapeutic Systems, Inc.	Stabilized preparations for use in metered dose inhalers
US6541606B2 (en)	1997-12-31	2003-04-01	Altus Biologics Inc.	Stabilized protein crystals formulations containing them and methods of making them
TW581681B (en)	1998-02-20	2004-04-01	Nektar Therapeutics	Liquid crystal forms of cyclosporin
EP2311436A1 (en)	1998-04-27	2011-04-20	Altus Pharmaceuticals Inc.	Stabilized protein crystals, formulations containing them and methods of making them
WO1999055362A1 (en) *	1998-04-29	1999-11-04	Genentech, Inc.	Spray dried formulations of igf-i
US6284282B1 (en)	1998-04-29	2001-09-04	Genentech, Inc.	Method of spray freeze drying proteins for pharmaceutical administration
GB9810559D0 (en) *	1998-05-15	1998-07-15	Bradford Particle Design Ltd	Method and apparatus for particle formation
US6451349B1 (en) *	1998-08-19	2002-09-17	Quadrant Healthcare (Uk) Limited	Spray-drying process for the preparation of microparticles
US6956021B1 (en) *	1998-08-25	2005-10-18	Advanced Inhalation Research, Inc.	Stable spray-dried protein formulations
US20070212422A1 (en) *	1999-11-10	2007-09-13	Manfred Keller	Dry powder for inhalation
ES2261195T3 (es) *	1999-04-05	2006-11-16	Mannkind Corporation	Metodo de formacion de particulas finas.
EP1169053A1 (en) *	1999-04-13	2002-01-09	Inhale Therapeutic Systems, Inc.	Pulmonary administration of dry powder formulations for treating infertility
WO2000061178A1 (en) *	1999-04-13	2000-10-19	Inhale Therapeutics Systems, Inc.	Pulmonary administration of dry powder formulations for treating infertility
ATE555773T1 (de)	1999-06-09	2012-05-15	Sievers Robert E	Überkritische fluidgestützte verneblung und blasen trochnen
US6858199B1 (en) *	2000-06-09	2005-02-22	Advanced Inhalation Research, Inc.	High efficient delivery of a large therapeutic mass aerosol
US9006175B2 (en) *	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
ES2569916T3 (es) *	1999-06-29	2016-05-13	Mannkind Corporation	Formulaciones farmacéuticas que comprenden insulina complejada con una dicetopiperazina
EP1196236B1 (en) *	1999-06-30	2007-08-29	Nektar Therapeutics	Spray drying process and system for preparing dry powders
EP1074248A1 (en) *	1999-07-08	2001-02-07	Arnold Hilgers	Delivery system for biological material
ITMI991582A1 (it) *	1999-07-16	2001-01-16	Chiesi Farma Spa	Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
US20010036481A1 (en) *	1999-08-25	2001-11-01	Advanced Inhalation Research, Inc.	Modulation of release from dry powder formulations
US6586008B1 (en) *	1999-08-25	2003-07-01	Advanced Inhalation Research, Inc.	Use of simple amino acids to form porous particles during spray drying
US7252840B1 (en)	1999-08-25	2007-08-07	Advanced Inhalation Research, Inc.	Use of simple amino acids to form porous particles
US7678364B2 (en)	1999-08-25	2010-03-16	Alkermes, Inc.	Particles for inhalation having sustained release properties
AU763041B2 (en) *	1999-08-25	2003-07-10	Alkermes, Inc.	Modulation of release from dry powder formulations
US6749835B1 (en)	1999-08-25	2004-06-15	Advanced Inhalation Research, Inc.	Formulation for spray-drying large porous particles
DE60025019T2 (de)	1999-10-29	2006-08-24	Nektar Therapeutics, San Carlos	Trockenpulverzusammensetzungen mit verbesserter dispersivität
US7507687B2 (en) *	2000-03-22	2009-03-24	Cabot Corporation	Electrocatalyst powders, methods for producing powder and devices fabricated from same
ES2525087T5 (es)	2000-05-10	2018-06-28	Novartis Ag	Polvos basados en fosfolípidos para administración de fármacos
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US20030003057A1 (en) *	2000-07-07	2003-01-02	Jeffry Weers	Methods for administering leuprolide by inhalation
US8404217B2 (en)	2000-05-10	2013-03-26	Novartis Ag	Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7575761B2 (en) *	2000-06-30	2009-08-18	Novartis Pharma Ag	Spray drying process control of drying kinetics
WO2002009669A2 (en) *	2000-08-01	2002-02-07	Inhale Therapeutic Systems, Inc.	Apparatus and process to produce particles having a narrow size distribution and particles made thereby
TWI283182B (en) *	2000-08-07	2007-07-01	Nektar Therapeutics	Inhalable spray dried 4-helix bundle protein powders having minimized aggregation
AU2002224408B2 (en) *	2000-10-18	2007-08-23	Massachusetts Institute Of Technology	Methods and products related to pulmonary delivery of polysaccharides
EP1335661B1 (en)	2000-10-27	2009-05-06	Baxter Healthcare S.A.	Production of microspheres
GB0027357D0 (en)	2000-11-09	2000-12-27	Bradford Particle Design Plc	Particle formation methods and their products
DE60127175T2 (de) *	2000-12-21	2007-11-08	Nektar Therapeutics, San Carlos	Lagerstabile pulverzusammensetzungen mit interleukin-4 rezeptor
US20020141946A1 (en) *	2000-12-29	2002-10-03	Advanced Inhalation Research, Inc.	Particles for inhalation having rapid release properties
US6887462B2 (en)	2001-04-09	2005-05-03	Chiron Corporation	HSA-free formulations of interferon-beta
US6848197B2 (en)	2001-04-18	2005-02-01	Advanced Inhalation Research, Inc.	Control of process humidity to produce large, porous particles
US20070270579A1 (en) *	2001-05-18	2007-11-22	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050054596A1 (en) *	2001-11-30	2005-03-10	Mcswiggen James	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050287128A1 (en) *	2001-05-18	2005-12-29	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
US20050256068A1 (en) *	2001-05-18	2005-11-17	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US20050176664A1 (en) *	2001-05-18	2005-08-11	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
US20050119212A1 (en) *	2001-05-18	2005-06-02	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
US20060241075A1 (en) *	2001-05-18	2006-10-26	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
US20050182009A1 (en) *	2001-05-18	2005-08-18	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
US20050233344A1 (en) *	2001-05-18	2005-10-20	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
US20080161256A1 (en) *	2001-05-18	2008-07-03	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) *	2002-02-20	2005-07-07	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050159376A1 (en) *	2002-02-20	2005-07-21	Slrna Therapeutics, Inc.	RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
US20040198682A1 (en) *	2001-11-30	2004-10-07	Mcswiggen James	RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US20050267058A1 (en) *	2001-05-18	2005-12-01	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
US20050182007A1 (en) *	2001-05-18	2005-08-18	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050227935A1 (en) *	2001-05-18	2005-10-13	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
US20070042983A1 (en) *	2001-05-18	2007-02-22	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050282188A1 (en) *	2001-05-18	2005-12-22	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050014172A1 (en) *	2002-02-20	2005-01-20	Ivan Richards	RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20050143333A1 (en) *	2001-05-18	2005-06-30	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050222066A1 (en) *	2001-05-18	2005-10-06	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050288242A1 (en) *	2001-05-18	2005-12-29	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US20050203040A1 (en) *	2001-05-18	2005-09-15	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) *	2001-05-18	2009-04-14	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050233997A1 (en) *	2001-05-18	2005-10-20	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20050164968A1 (en) *	2001-05-18	2005-07-28	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
US20050159380A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
US20060019913A1 (en) *	2001-05-18	2006-01-26	Sirna Therapeutics, Inc.	RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US20050187174A1 (en) *	2001-05-18	2005-08-25	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20050176666A1 (en) *	2001-05-18	2005-08-11	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en)	2001-05-18	2018-06-12	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
NZ519403A (en) *	2001-06-21	2005-03-24	Pfizer Prod Inc	Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels
WO2003035028A1 (en) *	2001-10-19	2003-05-01	Nektar Therapeutics	Modulating charge density to produce improvements in the characteristics of spray-dried proteins
AU2002335046A1 (en) *	2001-10-19	2003-05-06	Inhale Therapeutic Systems, Inc.	The use of proton sequestering agents in drug formulations
CA2465675C (en) *	2001-11-20	2008-06-10	Advanced Inhalation Research, Inc.	Improved particulate compositions for pulmonary delivery
US20030099601A1 (en) *	2001-11-27	2003-05-29	Gordon Marc S.	Inhalation lung surfactant therapy
US20050075304A1 (en) *	2001-11-30	2005-04-07	Mcswiggen James	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20070203333A1 (en) *	2001-11-30	2007-08-30	Mcswiggen James	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20040138163A1 (en) *	2002-05-29	2004-07-15	Mcswiggen James	RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
JP2005514393A (ja)	2001-12-19	2005-05-19	ネクターセラピューティクス	アミノグリコシドの肺への供給
US20050042632A1 (en) *	2002-02-13	2005-02-24	Sirna Therapeutics, Inc.	Antibodies having specificity for nucleic acids
US20040014679A1 (en) *	2002-02-20	2004-01-22	Boehringer Ingelheim Pharma Gmbh & Co., Kg	Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
US9181551B2 (en)	2002-02-20	2015-11-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050137153A1 (en) *	2002-02-20	2005-06-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
US9657294B2 (en)	2002-02-20	2017-05-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2002316574B2 (en) *	2002-03-15	2008-05-01	Brandeis University	Central airway administration for systemic delivery of therapeutics
US20040063912A1 (en) *	2002-03-15	2004-04-01	The Brigham And Women's Hospital, Inc.	Central airway administration for systemic delivery of therapeutics
US6923175B2 (en)	2002-03-20	2005-08-02	Mannkind Corporation	Inhalation apparatus
US7008644B2 (en) *	2002-03-20	2006-03-07	Advanced Inhalation Research, Inc.	Method and apparatus for producing dry particles
US20050163725A1 (en) *	2002-03-20	2005-07-28	Blizzard Charles D.	Method for administration of growth hormone via pulmonary delivery
US20040009231A1 (en) *	2002-03-20	2004-01-15	Advanced Inhalation Research, Inc.	hGH (human growth hormone) formulations for pulmonary administration
EP1551852A4 (en) *	2002-04-25	2007-03-21	Momenta Pharmaceuticals Inc	METHOD AND PRODUCTS FOR MUCOSAL DELIVERY
GB0216562D0 (en) *	2002-04-25	2002-08-28	Bradford Particle Design Ltd	Particulate materials
US9339459B2 (en)	2003-04-24	2016-05-17	Nektar Therapeutics	Particulate materials
DE10234165B4 (de) *	2002-07-26	2008-01-03	Advanced Micro Devices, Inc., Sunnyvale	Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
US8110209B2 (en)	2002-12-20	2012-02-07	Xeris Pharmaceuticals Inc.	Intracutaneous injection
TR200502522T2 (tr) *	2002-12-31	2005-09-21	Nektar Therapeutics	Çözünmez bir aktif madde içeren farmasötik formülasyon
MXPA05007156A (es) *	2002-12-31	2005-09-21	Nektar Therapeutics	Formulacion farmaceuticas aerosolizable para terapia para infecciones fungicas.
KR100500675B1 (ko) *	2003-02-10	2005-07-11	주식회사 에이앤피사이언스	고유량 입자 분무장치
GB0304540D0 (en) *	2003-02-27	2003-04-02	Elan Drug Delivery Ltd	Particle formulation and its preparation
CA2523475C (en) *	2003-05-28	2013-02-05	Nektar Therapeutics	Pharmaceutical formulation comprising a water-insoluble active agent
US20050014230A1 (en) *	2003-07-16	2005-01-20	Ccl Holding Co., Ltd.	Preparation of fully human antibodies
DE602004000493T2 (de) *	2003-07-28	2006-08-31	Pioneer Hi-Bred International, Inc.	Vorrichtung und verfahren zur aufbringung von substanzen an geerntete futterpflanzen und getreide
US20050042178A1 (en) *	2003-08-18	2005-02-24	Boehringer Ingelheim International Gmbh	Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
US20050042179A1 (en) *	2003-08-18	2005-02-24	Boehringer Ingelheim International Gmbh	Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
US20050042180A1 (en) *	2003-08-18	2005-02-24	Boehringer Ingelheim International Gmbh	Powder formulation containing the CGRP antagonist 1 [N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2 (1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin, process for preparing and the use thereof as inhalation powder
US20050043247A1 (en) *	2003-08-18	2005-02-24	Boehringer Ingelheim International Gmbh	Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
GB0327723D0 (en) *	2003-09-15	2003-12-31	Vectura Ltd	Pharmaceutical compositions
US7560444B2 (en) *	2003-10-01	2009-07-14	Momenta Pharmaceuticals, Inc.	Polysaccharides for pulmonary delivery of active agents
US7338171B2 (en) *	2003-10-27	2008-03-04	Jen-Chuen Hsieh	Method and apparatus for visual drive control
WO2005044226A2 (en) *	2003-11-04	2005-05-19	Nectar Therapeutics	Lipid formulations for spontaneous drug encapsulation
KR20050056799A (ko) *	2003-12-10	2005-06-16	엘지.필립스 엘시디 주식회사	액정 표시패널의 실 패턴 구조
EP1701714A2 (en)	2004-01-07	2006-09-20	Nektar Therapeutics	Improved sustained release compositions for pulmonary administration of insulin
ES2584867T3 (es) *	2004-01-12	2016-09-29	Mannkind Corporation	Un método que reduce los niveles séricos de proinsulina en diabéticos de tipo 2
US20080248999A1 (en) *	2007-04-04	2008-10-09	Biodel Inc.	Amylin formulations
DE602005014962D1 (de) *	2004-03-12	2009-07-30	Biodel Inc	Insulinzusammensetzungen mit verbesserter wirkstoffabsorption
US20080090753A1 (en) *	2004-03-12	2008-04-17	Biodel, Inc.	Rapid Acting Injectable Insulin Compositions
PL2708225T3 (pl)	2004-04-23	2019-07-31	Cydex Pharmaceuticals, Inc.	Formulacja DPI zawierająca eter sulfoalkilowy cyklodekstryny
US7611709B2 (en)	2004-05-10	2009-11-03	Boehringer Ingelheim Pharma Gmbh And Co. Kg	1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7727962B2 (en)	2004-05-10	2010-06-01	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Powder comprising new compositions of oligosaccharides and methods for their preparation
US7723306B2 (en)	2004-05-10	2010-05-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US10508277B2 (en)	2004-05-24	2019-12-17	Sirna Therapeutics, Inc.	Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
MXPA06015220A (es) *	2004-06-21	2007-12-13	Nektar Therapeutics	Composiciones comprendiendo anfotericina b, metodos y sistemas.
US8513204B2 (en) *	2004-06-21	2013-08-20	Novartis Ag	Compositions comprising amphotericin B, mehods and systems
BRPI0513508B1 (pt)	2004-07-19	2021-06-01	Biocon Limited	Conjugados de insulina-oligômero, formulações e usos desses
US20060024272A1 (en)	2004-07-29	2006-02-02	Large Scale Biology Corporation	C-terminally truncated interferon
ATE486064T1 (de)	2004-08-20	2010-11-15	Mannkind Corp	Katalyse der diketopiperazinsynthese
KR20130066695A (ko) *	2004-08-23	2013-06-20	맨카인드 코포레이션	약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
SE0402345L (sv) *	2004-09-24	2006-03-25	Mederio Ag	Uppmätt läkemedelsdos
US8968576B2 (en) *	2004-11-30	2015-03-03	The Administrators Of The Tulane Educational Fund	Nebulizing treatment method
US9149433B2 (en) *	2004-11-30	2015-10-06	Basf Corporation	Method for formation of micro-prilled polymers
WO2006076097A2 (en) *	2004-12-07	2006-07-20	Nektar Therapeutics	Stable non-crystalline formulation comprising losartan
US20080213593A1 (en) *	2005-01-21	2008-09-04	President And Fellows Of Harvard College	Systems And Methods For Forming Fluidic Droplets Encapsulated In Particles Such As Colloidal Particles
EP1866407A4 (en) *	2005-03-22	2010-07-14	Regeron Inc	DEVICE AND METHOD FOR SUBMICRONIZING PROTEINS USING SUPERCRITICAL LIQUIDS
CN101184522B (zh)	2005-05-18	2011-12-21	尼克塔治疗公司	用于支气管内治疗的阀、设备和方法
WO2007019554A2 (en) *	2005-08-08	2007-02-15	Momenta Pharmaceuticals, Inc.	Polysaccharides for delivery of active agents
MX373000B (es)	2005-09-14	2020-05-21	Mannkind Corp	Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
US8084420B2 (en) *	2005-09-29	2011-12-27	Biodel Inc.	Rapid acting and long acting insulin combination formulations
US7713929B2 (en)	2006-04-12	2010-05-11	Biodel Inc.	Rapid acting and long acting insulin combination formulations
WO2007041481A1 (en) *	2005-09-29	2007-04-12	Biodel, Inc.	Rapid acting and prolonged acting insulin preparations
US7629331B2 (en)	2005-10-26	2009-12-08	Cydex Pharmaceuticals, Inc.	Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
JP5096363B2 (ja)	2005-12-16	2012-12-12	ネクターセラピューティックス	Ｇｌｐ−１のポリマ複合体
US9012605B2 (en)	2006-01-23	2015-04-21	Amgen Inc.	Crystalline polypeptides
KR101501780B1 (ko) *	2006-01-24	2015-03-16	넥스바이오, 인코퍼레이티드	고분자 미소 구체들의 조제를 위한 기술
GB0602897D0 (en) *	2006-02-13	2006-03-22	Jagotec Ag	Improvements In Or Relating To Dry Powder Inhaler Devices
EP1986679B1 (en) *	2006-02-22	2017-10-25	MannKind Corporation	A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
WO2007121256A2 (en) *	2006-04-12	2007-10-25	Biodel, Inc.	Rapid acting and long acting insulin combination formulations
WO2008051570A1 (en)	2006-10-23	2008-05-02	Starkey Laboratories, Inc.	Entrainment avoidance with an auto regressive filter
GB0622818D0 (en) *	2006-11-15	2006-12-27	Jagotec Ag	Improvements in or relating to organic compounds
GB0625303D0 (en) *	2006-12-19	2007-01-24	Jagotec Ag	Improvements in and relating to metered dose inhalers
US7985058B2 (en) *	2007-01-12	2011-07-26	Mark Gray	Method and apparatus for making uniformly sized particles
WO2008137747A1 (en)	2007-05-02	2008-11-13	The Regents Of The University Of Michigan	Nanoemulsion therapeutic compositions and methods of using the same
US8273561B2 (en)	2007-10-05	2012-09-25	Nuron Biotech, Inc.	High pressure treatment of aggregated interferons
AU2008340304B2 (en) *	2007-12-21	2016-03-03	Aptevo Biotherapeutics Llc	Stabilized factor IX formulations containing trehalose
EP2077132A1 (en)	2008-01-02	2009-07-08	Boehringer Ingelheim Pharma GmbH & Co. KG	Dispensing device, storage device and method for dispensing a formulation
US20090175840A1 (en) *	2008-01-04	2009-07-09	Biodel, Inc.	Insulin formulations for insulin release as a function of tissue glucose levels
US8986253B2 (en)	2008-01-25	2015-03-24	Tandem Diabetes Care, Inc.	Two chamber pumps and related methods
WO2009140587A1 (en)	2008-05-15	2009-11-19	Novartis Ag	Pulmonary delivery of a fluoroquinolone
CN101827626B (zh)	2008-06-13	2015-03-18	曼金德公司	干粉吸入器和用于药物输送的系统
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
ES2421385T3 (es)	2008-06-20	2013-09-02	Mannkind Corp	Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI532497B (zh)	2008-08-11	2016-05-11	曼凱公司	超快起作用胰島素之用途
US8408421B2 (en)	2008-09-16	2013-04-02	Tandem Diabetes Care, Inc.	Flow regulating stopcocks and related methods
AU2009293019A1 (en)	2008-09-19	2010-03-25	Tandem Diabetes Care Inc.	Solute concentration measurement device and related methods
EP2341942A1 (en)	2008-09-19	2011-07-13	Nektar Therapeutics	Polymer conjugates of therapeutic peptides
EP2349209A2 (en) *	2008-09-26	2011-08-03	Nanobio Corporation	Nanoemulsion therapeutic compositions and methods of using the same
CA2736907C (en)	2008-10-03	2018-06-05	E.I. Du Pont De Nemours And Company	Improved perhydrolases for enzymatic peracid generation
US9974844B2 (en)	2008-11-17	2018-05-22	The Regents Of The University Of Michigan	Cancer vaccine compositions and methods of using the same
US9827205B2 (en) *	2008-12-12	2017-11-28	Mallinckrodt Pharma Ip Trading D.A.C.	Dry powder fibrin sealant
EP2379511B1 (en)	2008-12-29	2014-12-17	MannKind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
US9250106B2 (en)	2009-02-27	2016-02-02	Tandem Diabetes Care, Inc.	Methods and devices for determination of flow reservoir volume
AU2010217760B2 (en)	2009-02-27	2015-04-09	Tandem Diabetes Care, Inc.	Methods and devices for determination of flow reservoir volume
US9060927B2 (en) *	2009-03-03	2015-06-23	Biodel Inc.	Insulin formulations for rapid uptake
DK2405963T3 (da)	2009-03-11	2013-12-16	Mannkind Corp	Apparat, system og fremgangsmåde til at måle modstand i en inhalator
CA2835771C (en)	2009-03-18	2017-01-24	Incarda Therapeutics, Inc.	Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2010107952A2 (en)	2009-03-19	2010-09-23	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2408458A1 (en)	2009-03-19	2012-01-25	Merck Sharp&Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2408917A2 (en)	2009-03-19	2012-01-25	Merck Sharp&Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
EP2408915A2 (en)	2009-03-19	2012-01-25	Merck Sharp&Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521760A (ja)	2009-03-27	2012-09-20	メルク・シャープ・エンド・ドーム・コーポレイション	低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
AU2010229847A1 (en)	2009-03-27	2011-10-13	Merck Sharp & Dohme Corp.	RNA interference mediated inhibition of the intercellular adhesion molecule 1 (ICAM-1)gene expression using short interfering nucleic acid (siNA)
US20120004281A1 (en)	2009-03-27	2012-01-05	Merck Sharp & Dohme Corp	RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
JP2012521764A (ja)	2009-03-27	2012-09-20	メルク・シャープ・エンド・ドーム・コーポレイション	低分子干渉核酸（ｓｉＮＡ）を用いた胸腺間質性リンパ球新生因子（ＴＳＬＰ）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010111471A2 (en)	2009-03-27	2010-09-30	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US10011906B2 (en)	2009-03-31	2018-07-03	Beohringer Ingelheim International Gmbh	Method for coating a surface of a component
US20100266643A1 (en)	2009-04-01	2010-10-21	Willett W Scott	Pulmonary and nasal delivery of serum amyloid p
WO2010133294A2 (de)	2009-05-18	2010-11-25	Boehringer Ingelheim International Gmbh	Adapter, inhalationseinrichtung und zerstäuber
WO2010142017A1 (en)	2009-06-09	2010-12-16	Defyrus, Inc .	Administration of interferon for prophylaxis against or treatment of pathogenic infection
KR102584844B1 (ko)	2009-06-12	2023-10-04	맨카인드 코포레이션	한정된 비표면적을 갖는 디케토피페라진 마이크로입자
EP3284494A1 (en)	2009-07-30	2018-02-21	Tandem Diabetes Care, Inc.	Portable infusion pump system
US8222012B2 (en)	2009-10-01	2012-07-17	E. I. Du Pont De Nemours And Company	Perhydrolase for enzymatic peracid production
CA2778698A1 (en)	2009-11-03	2011-05-12	Mannkind Corporation	An apparatus and method for simulating inhalation efforts
TR201809898T4 (tr)	2009-11-03	2018-07-23	Grifols Therapeutics Llc	Alfa-1 protei̇naz i̇nhi̇bi̇törüne yöneli̇k bi̇leşi̇m, yöntem ve ki̇t.
US10016568B2 (en)	2009-11-25	2018-07-10	Boehringer Ingelheim International Gmbh	Nebulizer
JP5658268B2 (ja)	2009-11-25	2015-01-21	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ネブライザ
EA026241B1 (ru)	2009-11-25	2017-03-31	Бёрингер Ингельхайм Интернациональ Гмбх	Распылитель
ES2622462T3 (es) *	2009-12-03	2017-07-06	Purac Biochem Bv	Polvo de cinamato de metal alcalino y procedimiento de preparación del mismo
KR101718534B1 (ko)	2009-12-09	2017-03-22	닛토덴코 가부시키가이샤	Ｈｓｐ４７ 발현의 조절
CN101816913B (zh) *	2010-05-20	2015-10-21	吴传斌	一种微球制造方法及制造设备
CN102985125A (zh)	2010-06-21	2013-03-20	曼金德公司	干粉药物输送系统和方法
WO2011160932A1 (en)	2010-06-24	2011-12-29	Boehringer Ingelheim International Gmbh	Nebulizer
WO2012012460A1 (en)	2010-07-19	2012-01-26	Xeris Pharmaceuticals, Inc.	Stable glucagon formulations for the treatment of hypoglycemia
KR101758424B1 (ko)	2010-09-24	2017-07-14	유니버시티 오브 플로리다 리서치 파운데이션, 인크.	위장 기능을 증진시키기 위한 물질 및 방법
WO2012058210A1 (en)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
CN103429228B (zh)	2011-01-05	2016-10-26	赫士睿股份有限公司	万古霉素的喷雾干燥
US8845902B2 (en) *	2011-02-10	2014-09-30	Crucell Holland B.V.	Pneumatic alternating pressure membrane cell separation system
MX350838B (es)	2011-02-11	2017-09-18	Grain Proc Corporation *	Composicion de sal.
US8708159B2 (en) *	2011-02-16	2014-04-29	Oakwood Laboratories, Llc	Manufacture of microspheres using a hydrocyclone
US10307549B2 (en)	2011-02-25	2019-06-04	Koninklijke Philips N.V.	Aerosol generating device for nebulizing a liquid and a method of temperature control of a liquid to be nebulized
CN103492572A (zh)	2011-03-03	2014-01-01	夸克医药公司	用于治疗肺疾病和损伤的组合物和方法
EP3225235B1 (en)	2011-03-10	2020-12-16	Xeris Pharmaceuticals, Inc.	Stable peptide formulations for parenteral injection
EP2683364B1 (en)	2011-03-10	2017-01-18	Xeris Pharmaceuticals, Inc.	Stable formulations for parenteral injection of peptide drugs
WO2012130757A1 (de)	2011-04-01	2012-10-04	Boehringer Ingelheim International Gmbh	Medizinisches gerät mit behälter
SG194034A1 (en)	2011-04-01	2013-11-29	Mannkind Corp	Blister package for pharmaceutical cartridges
US9572774B2 (en)	2011-05-19	2017-02-21	Savara Inc.	Dry powder vancomycin compositions and associated methods
EP2709646A4 (en) *	2011-05-19	2015-05-13	Savara Inc	DRY POWDER VANCOMYCIN COMPOSITIONS AND RELATED METHODS
US9827384B2 (en)	2011-05-23	2017-11-28	Boehringer Ingelheim International Gmbh	Nebulizer
US9011903B2 (en)	2011-06-08	2015-04-21	Nitto Denko Corporation	Cationic lipids for therapeutic agent delivery formulations
US10196637B2 (en)	2011-06-08	2019-02-05	Nitto Denko Corporation	Retinoid-lipid drug carrier
TWI658830B (zh)	2011-06-08	2019-05-11	日東電工股份有限公司	Ｈｓｐ47表現調控強化用類視色素脂質體
CN107043334B (zh)	2011-06-08	2020-06-16	日东电工株式会社	用于定向药物输送和增强siRNA活性的化合物
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
MX2014004983A (es)	2011-10-24	2014-09-22	Mannkid Corp	Metodos y composiciones para tratar dolor.
SG10201604104PA (en)	2011-10-25	2016-07-28	Prothena Therapeutics Ltd	Antibody formulations and methods
WO2013067022A1 (en)	2011-10-31	2013-05-10	Xeris Pharmaceuticals, Inc.	Formulations for the treatment of diabetes
US9643996B2 (en) *	2011-11-04	2017-05-09	Battelle Memorial Institute	Processes for producing protein microparticles
EP2601941A1 (en)	2011-12-06	2013-06-12	Ludwig-Maximilians-Universität München	Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
RU2615076C2 (ru)	2011-12-16	2017-04-03	Новартис Аг	Устройство аэрозолизации для независимой от профиля вдоха доставки лекарственного средства
US9603907B2 (en)	2012-02-01	2017-03-28	Protalix Ltd.	Dry powder formulations of dNase I
WO2013151744A1 (en)	2012-04-05	2013-10-10	University Of Florida Research Foundation, Inc.	Materials and methods for treatment of cystic fibrosis and for induction of ion secretion
US8753643B1 (en)	2012-04-11	2014-06-17	Life-Science Innovations, Llc	Spray dried compositions and methods of use
RU2666963C2 (ru)	2012-04-13	2018-09-13	Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед	Агрегированные частицы
WO2013152894A1 (de)	2012-04-13	2013-10-17	Boehringer Ingelheim International Gmbh	Zerstäuber mit kodiermitteln
US9180242B2 (en)	2012-05-17	2015-11-10	Tandem Diabetes Care, Inc.	Methods and devices for multiple fluid transfer
US9555186B2 (en)	2012-06-05	2017-01-31	Tandem Diabetes Care, Inc.	Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9125805B2 (en)	2012-06-27	2015-09-08	Xeris Pharmaceuticals, Inc.	Stable formulations for parenteral injection of small molecule drugs
EP2866792A4 (en)	2012-06-28	2016-08-17	Ansun Biopharma Inc	MICROPARTICLE FORMULATIONS FOR DELIVERY TO LOWER AND CENTRAL RESPIRATORY PATHS AND METHOD OF PREPARING THEM
KR102264177B1 (ko)	2012-07-12	2021-06-11	맨카인드 코포레이션	건조 분말 약물 전달 시스템 및 방법
WO2014066856A1 (en)	2012-10-26	2014-05-01	Mannkind Corporation	Inhalable influenza vaccine compositions and methods
US9757529B2 (en)	2012-12-20	2017-09-12	Otitopic Inc.	Dry powder inhaler and methods of use
US9757395B2 (en)	2012-12-20	2017-09-12	Otitopic Inc.	Dry powder inhaler and methods of use
US9018162B2 (en)	2013-02-06	2015-04-28	Xeris Pharmaceuticals, Inc.	Methods for rapidly treating severe hypoglycemia
US9956287B2 (en)	2013-02-06	2018-05-01	Perosphere Inc.	Stable glucagon formulations
KR101969199B1 (ko)	2013-03-11	2019-04-15	유니버시티 오브 플로리다 리서치 파운데이션, 인크.	폐 기능의 개선 및 방사선 유발된 폐 합병증의 예방 및/또는 치료를 위한 물질 및 방법
US9173998B2 (en)	2013-03-14	2015-11-03	Tandem Diabetes Care, Inc.	System and method for detecting occlusions in an infusion pump
CN104043104B (zh)	2013-03-15	2018-07-10	浙江创新生物有限公司	含盐酸万古霉素的喷雾干粉及其工业化制备方法
EP3587404B1 (en)	2013-03-15	2022-07-13	MannKind Corporation	Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
HK1218720A1 (zh)	2013-04-30	2017-03-10	欧缇托匹克公司	干粉制剂及使用方法
WO2014207213A1 (en)	2013-06-28	2014-12-31	Medizinische Universität Innsbruck	Novel inhibitors of protein kinase c epsilon signaling
MX375448B (es)	2013-07-18	2025-03-06	Mannkind Corp	Composiciones farmacéuticas en polvo seco estables al calor y métodos.
EP3030294B1 (en)	2013-08-05	2020-10-07	MannKind Corporation	Insufflation apparatus
EP3030298B1 (en)	2013-08-09	2017-10-11	Boehringer Ingelheim International GmbH	Nebulizer
PL2835146T3 (pl)	2013-08-09	2021-04-06	Boehringer Ingelheim International Gmbh	Nebulizator
ES2922206T3 (es)	2014-02-20	2022-09-09	Otitopic Inc	Formulaciones de polvo seco para la inhalación
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
EA035261B1 (ru)	2014-05-07	2020-05-21	Бёрингер Ингельхайм Интернациональ Гмбх	Небулайзер и контейнер
HUE055604T2 (hu)	2014-05-07	2021-12-28	Boehringer Ingelheim Int	Porlasztó
AU2015257878B2 (en)	2014-05-07	2019-08-08	Boehringer Ingelheim International Gmbh	Container, nebulizer and use
EP2947460A1 (en)	2014-05-22	2015-11-25	Medizinische Universität Wien	Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
CN106794156B (zh)	2014-07-08	2021-03-09	美药星制药股份有限公司	微粒化胰岛素、微粒化胰岛素类似物及其制备方法
EP3185932A1 (en)	2014-08-06	2017-07-05	Xeris Pharmaceuticals, Inc.	Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
US10575417B2 (en)	2014-09-08	2020-02-25	The Stanley Works Israel Ltd.	Jobsite communications center
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
EP4112076A1 (en)	2014-10-10	2023-01-04	The Regents of The University of Michigan	Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
US20170304459A1 (en)	2014-10-10	2017-10-26	Alnylam Pharmaceuticals, Inc.	Methods and compositions for inhalation delivery of conjugated oligonucleotide
WO2016067252A1 (en)	2014-10-31	2016-05-06	Glaxosmithkline Intellectual Property Development Limited	Powder formulation
EP3459540A1 (en)	2014-11-24	2019-03-27	Entrinsic Health Solutions, Inc.	Amino acid compositions for the treatment of symptoms of disease
IL253208B2 (en)	2015-01-04	2023-03-01	Protalix Ltd	Converted DNase and its uses
WO2016135138A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135139A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135137A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016170102A1 (en)	2015-04-22	2016-10-27	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
CN108704200A (zh) *	2015-05-16	2018-10-26	苏州汉方医药有限公司	由手动悬浮微颗粒发生器和白花蛇舌草或白花蛇舌草素组成的药盒
US9649364B2 (en)	2015-09-25	2017-05-16	Xeris Pharmaceuticals, Inc.	Methods for producing stable therapeutic formulations in aprotic polar solvents
WO2016196976A1 (en)	2015-06-04	2016-12-08	Xeris Pharmaceuticals, Inc.	Glucagon delivery apparatuses and related methods
EP3307295A1 (en)	2015-06-10	2018-04-18	Xeris Pharmaceuticals, Inc.	Use of low dose glucagon
US11590205B2 (en)	2015-09-25	2023-02-28	Xeris Pharmaceuticals, Inc.	Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
MX377528B (es)	2015-12-09	2025-03-10	Univ Wien Med	Compuestos de platino funcionalizados con monomaleimida para la terapia del cáncer.
CN106968984B (zh) *	2015-12-11	2020-10-23	松下知识产权经营株式会社	涡轮机
US10322168B2 (en)	2016-01-07	2019-06-18	Amphastar Pharmaceuticals, Inc.	High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
AU2017207867A1 (en)	2016-01-15	2018-08-09	Universität Hamburg	Flavonoide-type compounds bearing an O-rhamnosyl residue
US11833118B2 (en)	2016-01-20	2023-12-05	Flurry Powders, Llc	Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
JP6953414B2 (ja)	2016-01-20	2021-10-27	フラリーパウダーズエルエルシーＦｌｕｒｒｙＰｏｗｄｅｒｓ，Ｌｌｃ	親油性成分を含む吸入に好適な分散性の噴霧乾燥粉末を製造する方法
CN114847965A (zh)	2016-02-01	2022-08-05	英凯达治疗公司	电子监测联合吸入药理学疗法管理心律失常
MX2018009870A (es)	2016-02-15	2018-11-29	Cemm Forschungszentrum Fuer Molekulare Medizin Gmbh	Inhibidores de taf1 para la terapia del cancer.
ES2957548T3 (es)	2016-04-15	2024-01-22	Univ Oxford Innovation Ltd	Moduladores del receptor de adenosina para el tratamiento de los trastornos del ritmo circadiano
US10704425B2 (en) *	2016-07-14	2020-07-07	General Electric Company	Assembly for a gas turbine engine
EP3522882A4 (en)	2016-10-04	2020-06-24	The University of Florida Research Foundation Incorporated	AMINO ACID COMPOSITIONS AND USES THEREOF
WO2018087401A2 (en)	2016-11-14	2018-05-17	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Combination of a brd4 inhibitor and an antifolate for the therapy of cancer
CA3060702A1 (en)	2017-05-10	2018-11-15	Incarda Therapeutics, Inc.	Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
GB2577420B (en)	2017-05-22	2022-07-06	Insmed Inc	Glycopeptide derivative compounds and uses thereof
US11020403B2 (en)	2017-06-02	2021-06-01	Xeris Pharmaceuticals, Inc.	Precipitation resistant small molecule drug formulations
WO2019016240A1 (en)	2017-07-19	2019-01-24	Leadiant Biosciences Ltd	ADENOSINE DEAMINASE FOR TREATING OR IMPROVING SCLERRODERMIS ASSOCIATED VASCULOPATHY
EP3720850A1 (en)	2017-12-05	2020-10-14	ETH Zurich	New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
ES3040411T3 (en)	2018-03-22	2025-10-30	Incarda Therapeutics Inc	A novel method to slow ventricular rate
US20210163406A1 (en)	2018-04-06	2021-06-03	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
JP7611812B2 (ja)	2018-04-06	2025-01-10	ツィレンティンアーゲー	多汗症を治療するためのブメタニド誘導体
DK3599243T3 (da)	2018-07-26	2023-07-10	Cvie Therapeutics Ltd	17beta-heterocyklyl-digitalis-lignende forbindelser til behandlingen af hjertesvigt
AU2019407650B2 (en)	2018-12-17	2022-10-27	Tolremo Therapeutics Ag	Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
JP7455144B2 (ja)	2019-04-29	2024-03-25	インスメッドインコーポレイテッド	トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法
RU193395U1 (ru) *	2019-06-17	2019-10-28	Евгений Викторович Крейдин	Генератор сухого солевого аэрозоля
KR102891439B1 (ko)	2019-08-01	2025-11-25	인카다 테라퓨틱스, 인크.	항부정맥 제제
US11007185B2 (en)	2019-08-01	2021-05-18	Incarda Therapeutics, Inc.	Antiarrhythmic formulation
WO2021064141A1 (en)	2019-10-02	2021-04-08	Tolremo Therapeutics Ag	Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
US12478624B2 (en)	2019-10-02	2025-11-25	Tolremo Therapeutics Ag	Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
DK3805243T3 (da)	2019-10-09	2024-01-02	Windtree Therapeutics Inc	Androstanderivater med aktivitet som rene eller hovedsageligt rene stimulatorer af serca2a til behandling af hjertesvigt
WO2021074414A1 (en)	2019-10-16	2021-04-22	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
WO2021074418A1 (en)	2019-10-16	2021-04-22	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
WO2021216547A1 (en)	2020-04-20	2021-10-28	Sorrento Therapeutics, Inc.	Pulmonary administration of ace2 polypeptides
CA3184062A1 (en)	2020-06-25	2021-12-30	Stefanie Fluckiger-Mangual	Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
IL299344A (en)	2020-06-25	2023-02-01	Tolremo Therapeutics Ag	Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
JP2023532888A (ja)	2020-06-27	2023-08-01	クレセンタバイオサイエンシズ	細胞代謝を調節する化合物の組成及び使用方法
EP3939578A1 (en)	2020-07-13	2022-01-19	Novaremed Ltd.	Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
EP3964497A1 (en)	2020-09-04	2022-03-09	Friedrich-Alexander-Universität Erlangen-Nürnberg	Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
CN116635056A (zh)	2020-10-07	2023-08-22	波塔力克斯有限公司	长效脱氧核糖核酸酶
WO2022079290A2 (en)	2020-10-16	2022-04-21	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Cullin ring ubiquitin ligase compounds and uses thereof
KR20230096998A (ko)	2020-10-28	2023-06-30	인스메드 인코포레이티드	트레프로스티닐 전구약물의 건조 분말 조성물 및 이의 사용 방법
BR112023020538A2 (pt)	2021-04-07	2024-01-23	Tolremo Therapeutics Ag	Derivados heterocíclicos, composições farmacêuticas e seus usos no tratamento ou na melhoria de câncer
US12138243B2 (en)	2021-12-31	2024-11-12	Crescenta Biosciences	Antiviral use of FABP4 modulating compounds
WO2023150747A1 (en)	2022-02-07	2023-08-10	Insmed Incorporated	Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023203174A1 (en)	2022-04-20	2023-10-26	Proxygen Gmbh	Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
WO2025040546A1 (en)	2023-08-18	2025-02-27	Proxygen Gmbh	Pyrazole compounds as cullin ring ubiquitin ligase compounds
WO2025104236A1 (en)	2023-11-15	2025-05-22	Proxygen Gmbh	Pyrazole compounds as cullin ring ubiquitin ligase compounds
GB202319534D0 (en)	2023-12-19	2024-01-31	Circadian Therapeutics Ltd	Dosage regimen

Family Cites Families (206)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE421211A (2)	1936-05-02
GB621785A (en)	1943-07-27	1949-04-20	Teco Sa	Apparatus for the pulverisation of liquids in the form of aerosols
US2598525A (en) *	1950-04-08	1952-05-27	E & J Mfg Co	Automatic positive pressure breathing machine
US3362405A (en) *	1964-04-06	1968-01-09	Hamilton O. Hazel	Method and apparatus for admixing gas with solid particles
US3674901A (en) *	1966-07-26	1972-07-04	Nat Patent Dev Corp	Surgical sutures
US3425600A (en) *	1966-08-11	1969-02-04	Abplanalp Robert H	Pressurized powder dispensing device
DE2121066C3 (de)	1971-04-29	1974-05-30	Knapsack Ag, 5033 Huerth-Knapsack	Zerstäubungsdüse für einen Zerstäubungstrockner
US4052255A (en)	1971-10-07	1977-10-04	J. M. Huber Corporation	Spray dryer discharge system
US3790079A (en)	1972-06-05	1974-02-05	Rnb Ass Inc	Method and apparatus for generating monodisperse aerosol
US3825188A (en)	1973-03-23	1974-07-23	Par Wey Mfg Co	Liquid spray head
US4069819A (en) *	1973-04-13	1978-01-24	Societa Farmaceutici S.P.A.	Inhalation device
GB1479283A (en) *	1973-07-23	1977-07-13	Bespak Industries Ltd	Inhaler for powdered medicament
FR2257351A1 (en)	1974-01-11	1975-08-08	Obert Jean Claude	Aerosol device for solid vaccines - feed and breaker screws deliver material sideways into blower chamber
IT1016489B (it) *	1974-03-18	1977-05-30	Isf Spa	Inalatore
SU628930A1 (ru)	1974-11-26	1978-10-25	Московский научно-исследовательский институт туберкулеза	Устройство дл введени порошкообразного лекарственного вещества
US4005711A (en) *	1975-01-13	1977-02-01	Syntex Puerto Rico, Inc.	Inhalation device
US3964483A (en) *	1975-01-13	1976-06-22	Syntex Puerto Rico, Inc.	Inhalation device
FR2299011A1 (fr) *	1975-01-29	1976-08-27	Obert Jean Claude	Generateur d'aerosols de part
US3991304A (en) *	1975-05-19	1976-11-09	Hillsman Dean	Respiratory biofeedback and performance evaluation system
US4153689A (en) *	1975-06-13	1979-05-08	Takeda Chemical Industries, Ltd.	Stable insulin preparation for nasal administration
US4035317A (en)	1975-06-30	1977-07-12	American Cyanamid Company	Rapidly dissolving, water-soluble polymers and spray drying method for their production
GB1527605A (en)	1975-08-20	1978-10-04	Takeda Chemical Industries Ltd	Insulin preparation for intranasal administration
US3994421A (en) *	1975-09-29	1976-11-30	American Cyanamid Company	Unitary therapeutic aerosol dispenser
JPS5254709A (en)	1975-10-31	1977-05-04	Lion Corp	Multi-stage spray drying method
DK150716C (da)	1976-12-01	1987-10-26	Niro Atomizer As	Fremgangsmaade ved behandling af et pulver- eller partikelformet produkt og apparat til brug ved udoevelse af fremgangsmaaden
FI54093C (fi)	1976-12-20	1978-10-10	Outokumpu Oy	Saett att framstaella pulverformigt selen fraon raoselen
US4211769A (en) *	1977-08-24	1980-07-08	Takeda Chemical Industries, Ltd.	Preparations for vaginal administration
NL7712041A (en)	1977-11-01	1979-05-03	Handelmaatschappij Voorheen Be	Suction equipment for powdery material - incorporates ejector type suction pump and cyclone type separator
JPS5829150B2 (ja)	1977-12-03	1983-06-21	ナカヤ産業株式会社	噴霧装置
US4268460A (en) *	1977-12-12	1981-05-19	Warner-Lambert Company	Nebulizer
EP0005585B1 (en) *	1978-05-03	1981-08-12	FISONS plc	Inhalation device
US4253468A (en) *	1978-08-14	1981-03-03	Steven Lehmbeck	Nebulizer attachment
US4503035B1 (en) *	1978-11-24	1996-03-19	Hoffmann La Roche	Protein purification process and product
SU1003926A1 (ru)	1979-01-24	1983-03-15	Всесоюзный Научно-Исследовательский И Конструкторский Институт Автогенного Машиностроения	Порошковый питатель
DE3013839A1 (de)	1979-04-13	1980-10-30	Freunt Ind Co Ltd	Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
IT1116047B (it) *	1979-04-27	1986-02-10	Sigma Tau Ind Farmaceuti	Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
JPS6034925B2 (ja) *	1979-07-31	1985-08-12	帝人株式会社	持続性鼻腔用製剤およびその製造法
JPS57500862A (2) *	1979-10-30	1982-05-20
US4294624A (en) *	1980-03-14	1981-10-13	Veltman Preston Leonard	Drying co-mingled carbohydrate solution and recycled product by dielectric heating
US4452239A (en) *	1980-03-25	1984-06-05	Hilal Malem	Medical nebulizing apparatus
US4484577A (en) *	1981-07-23	1984-11-27	Key Pharmaceuticals, Inc.	Drug delivery method and inhalation device therefor
GB2105189B (en)	1981-07-24	1985-03-20	Fisons Plc	Inhalation drugs
EP0072046B1 (en) *	1981-07-24	1986-01-15	FISONS plc	Inhalation drugs, methods for their production and pharmaceutical formulations containing them
US5260306A (en) *	1981-07-24	1993-11-09	Fisons Plc	Inhalation pharmaceuticals
KR890000664B1 (ko)	1981-10-19	1989-03-22	바리 안소니 뉴우샘	미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
CH656077A5 (de)	1982-01-29	1986-06-13	Glatt Maschinen & Apparatebau	Verfahren zum ueberziehen von teilchen, insbesondere arzneimittel-teilchen, und vorrichtung zur durchfuehrung des verfahrens.
US4659696A (en) *	1982-04-30	1987-04-21	Takeda Chemical Industries, Ltd.	Pharmaceutical composition and its nasal or vaginal use
US4823784A (en) *	1982-04-30	1989-04-25	Cadema Medical Products, Inc.	Aerosol inhalation apparatus
DK172541B1 (da) *	1982-10-08	1998-12-07	Glaxo Group Ltd	Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet
JPS59163313A (ja) *	1983-03-09	1984-09-14	Teijin Ltd	経鼻投与用ペプチドホルモン類組成物
CA1200416A (en) *	1983-05-13	1986-02-11	Societe Des Produits Nestle S.A.	Food process
US4486435A (en)	1983-05-16	1984-12-04	Basf Wyandotte Corporation	Spray-dried vitamin powders using hydrophobic silica
US5038769A (en)	1983-06-29	1991-08-13	Krauser Robert S	Method and apparatus for treating ailments
US4649911A (en) *	1983-09-08	1987-03-17	Baylor College Of Medicine	Small particle aerosol generator for treatment of respiratory disease including the lungs
DE3345722A1 (de) *	1983-12-17	1985-06-27	Boehringer Ingelheim KG, 6507 Ingelheim	Inhalator
US4534343A (en) *	1984-01-27	1985-08-13	Trutek Research, Inc.	Metered dose inhaler
US4721709A (en)	1984-07-26	1988-01-26	Pyare Seth	Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
US4624251A (en) *	1984-09-13	1986-11-25	Riker Laboratories, Inc.	Apparatus for administering a nebulized substance
NZ209900A (en) *	1984-10-16	1989-08-29	Univ Auckland	Automatic inhaler
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
FR2575678B1 (fr) *	1985-01-04	1988-06-03	Saint Gobain Vitrage	Ejecteur pneumatique de poudre
US4942544A (en) *	1985-02-19	1990-07-17	Kenneth B. McIntosh	Medication clock
US4946828A (en) *	1985-03-12	1990-08-07	Novo Nordisk A/S	Novel insulin peptides
IL78342A (en) *	1985-04-04	1991-06-10	Gen Hospital Corp	Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE3682457D1 (de) *	1985-07-30	1991-12-19	Glaxo Group Ltd	Geraet zur verabreichung von medikamenten an patienten.
US4702799A (en)	1985-09-03	1987-10-27	Nestec S.A.	Dryer and drying method
SE453566B (sv) *	1986-03-07	1988-02-15	Draco Ab	Anordning vid pulverinhalatorer
US5017372A (en) *	1986-04-14	1991-05-21	Medicis Corporation	Method of producing antibody-fortified dry whey
US4739754A (en) *	1986-05-06	1988-04-26	Shaner William T	Suction resistant inhalator
US4790305A (en) *	1986-06-23	1988-12-13	The Johns Hopkins University	Medication delivery system
US4926852B1 (en) *	1986-06-23	1995-05-23	Univ Johns Hopkins	Medication delivery system phase one
US5042975A (en) *	1986-07-25	1991-08-27	Rutgers, The State University Of New Jersey	Iontotherapeutic device and process and iontotherapeutic unit dose
EP0257915B1 (en) *	1986-08-11	1993-03-10	Innovata Biomed Limited	Pharmaceutical formulations comprising microcapsules
US4871489A (en)	1986-10-07	1989-10-03	Corning Incorporated	Spherical particles having narrow size distribution made by ultrasonic vibration
US4760093A (en)	1986-10-21	1988-07-26	American Home Products Corporation (Del.)	Spray dried acetaminophen
DE3636669C2 (de) *	1986-10-28	2001-08-16	Siemens Ag	Anordnung zur Zufuhr von Aerosol zu den Luftwegen und/oder Lungen eines Patienten
US5049388A (en) *	1986-11-06	1991-09-17	Research Development Foundation	Small particle aerosol liposome and liposome-drug combinations for medical use
US4833125A (en) *	1986-12-05	1989-05-23	The General Hospital Corporation	Method of increasing bone mass
DE3642106A1 (de)	1986-12-10	1988-06-16	Bayer Ag	Verfahren zur herstellung von polymerisatpulvern durch zerstaeubungstrocknung
NZ222907A (en)	1986-12-16	1990-08-28	Novo Industri As	Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5114917A (en) *	1986-12-24	1992-05-19	John Lezdey	Treatment of inflammation using alpha 1-antichymotrypsin
US4784878A (en)	1987-04-06	1988-11-15	Damrow Company, Inc.	Spray drying method and apparatus for concurrent particle coating
GB8710290D0 (en)	1987-04-30	1987-06-03	Unilever Plc	Preparation of granular detergent composition
GB8712176D0 (en)	1987-05-22	1987-06-24	Cosmas Damian Ltd	Drug delivery system
US4835187A (en)	1987-06-15	1989-05-30	American Home Products Corporation	Spray dried ibuprofen
US5139016A (en) *	1987-08-07	1992-08-18	Sorin Biomedica S.P.A.	Process and device for aerosol generation for pulmonary ventilation scintigraphy
IT1222509B (it) *	1987-08-17	1990-09-05	Miat Spa	Insufflatore per la somministrazione di farmaci sotto forma di polvere predosata in opercoli
CH672048A5 (2)	1987-09-16	1989-10-31	Nestle Sa
GB8723846D0 (en) *	1987-10-10	1987-11-11	Danbiosyst Ltd	Bioadhesive microsphere drug delivery system
WO1989004838A1 (en) *	1987-11-25	1989-06-01	Immunex Corporation	Interleukin-1 receptors
US5081228A (en) *	1988-02-25	1992-01-14	Immunex Corporation	Interleukin-1 receptors
US4968607A (en) *	1987-11-25	1990-11-06	Immunex Corporation	Interleukin-1 receptors
JP2524379B2 (ja)	1988-01-29	1996-08-14	大川原化工機株式会社	ノズル装置とそれを組込んでなるスプレ―ドライヤ―装置
ES2047547T3 (es)	1988-06-03	1994-03-01	Niro Sterner Inc	Metodo de deshidratacion por aspersion y aparato para revestimiento simultaneo de particulas.
IT1217890B (it) *	1988-06-22	1990-03-30	Chiesi Farma Spa	Dispositivo per l'inalazione di aerosol dosati
US5066522A (en)	1988-07-14	1991-11-19	Union Carbide Chemicals And Plastics Technology Corporation	Supercritical fluids as diluents in liquid spray applications of adhesives
EP0360340A1 (en) *	1988-09-19	1990-03-28	Akzo N.V.	Composition for nasal administration containing a peptide
ATE104867T1 (de) *	1988-10-04	1994-05-15	Univ Johns Hopkins	Inhalationsgeraet fuer aerosolen.
US4984158A (en) *	1988-10-14	1991-01-08	Hillsman Dean	Metered dose inhaler biofeedback training and evaluation system
DK479189D0 (da)	1989-01-06	1989-09-28	Hans Gernot Schenk	Inhalator
US5011678A (en) *	1989-02-01	1991-04-30	California Biotechnology Inc.	Composition and method for administration of pharmaceutically active substances
GB8903593D0 (en) *	1989-02-16	1989-04-05	Pafra Ltd	Storage of materials
IT1228459B (it) *	1989-02-23	1991-06-19	Phidea S R L	Inalatore con svuotamento regolare e completo della capsula.
GB8904370D0 (en)	1989-02-25	1989-04-12	Cosmas Damian Ltd	Liquid delivery compositions
SE466684B (sv) *	1989-03-07	1992-03-23	Draco Ab	Anordning vid en inhalator samt foerfarande foer att med anordningen registrera medicinering med inhalator
US5009367A (en)	1989-03-22	1991-04-23	Union Carbide Chemicals And Plastics Technology Corporation	Methods and apparatus for obtaining wider sprays when spraying liquids by airless techniques
US5206306A (en)	1989-03-31	1993-04-27	The B. F. Goodrich Company	Process for making a polymer for an optical substrate by hydrogenating a cycloolefin copolymer
FI84698C (fi)	1989-06-16	1992-01-10	Huhtamaeki Oy	Anordning foer finfoerdelning av agglomerat av en enkeldos av ett laekemedelpreparat i pulverform.
IT1230313B (it) *	1989-07-07	1991-10-18	Somova Spa	Inalatore per medicamenti in capsule.
US5232707A (en)	1989-07-10	1993-08-03	Syntex (U.S.A.) Inc.	Solvent extraction process
DE3927170A1 (de)	1989-08-17	1991-02-21	Boehringer Ingelheim Kg	Inhalator
GB8918879D0 (en)	1989-08-18	1989-09-27	Danbiosyst Uk	Pharmaceutical compositions
US5238920A (en) *	1989-08-22	1993-08-24	Abbott Laboratories	Pulmonary surfactant protein fragments
IT1237118B (it) *	1989-10-27	1993-05-18	Miat Spa	Inalatore multidose per farmaci in polvere.
US5707644A (en) *	1989-11-04	1998-01-13	Danbiosyst Uk Limited	Small particle compositions for intranasal drug delivery
GB9001635D0 (en) *	1990-01-24	1990-03-21	Ganderton David	Aerosol carriers
US5376386A (en) *	1990-01-24	1994-12-27	British Technology Group Limited	Aerosol carriers
US5113855A (en) *	1990-02-14	1992-05-19	Newhouse Michael T	Powder inhaler
DE4004904A1 (de) *	1990-02-16	1990-09-13	Gerhard Brendel	Trommel-applikator
JPH05507090A (ja) *	1990-05-08	1993-10-14	リポサーム　テクノロジー　インコーポレイテッド	直接噴霧乾燥された薬剤／脂質粉末組成物
US5000888A (en)	1990-05-23	1991-03-19	Basf Corporation	Process for spray drying riboflavin to produce a granulate product having low binder content
DE69112917T2 (de)	1990-06-15	1996-05-15	Merck & Co Inc	Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
IT1243344B (it) *	1990-07-16	1994-06-10	Promo Pack Sa	Inalatore plurimonodose per medicamenti in polvere
US5037912A (en) *	1990-07-26	1991-08-06	The Goodyear Tire & Rubber Company	Polymerization of 1,3-butadiene to trans-1,4-polybutadiene with organolithium and alkali metal alkoxide
GB9017155D0 (en)	1990-08-03	1990-09-19	Ici Plc	Spray drying
US5235969A (en) *	1990-08-20	1993-08-17	Intersurgical (Guernsey) Limited	Nebulizer having combined structure for removing particles over two microns
US5230884A (en) *	1990-09-11	1993-07-27	University Of Wales College Of Cardiff	Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5200399A (en) *	1990-09-14	1993-04-06	Boyce Thompson Institute For Plant Research, Inc.	Method of protecting biological materials from destructive reactions in the dry state
US5217004A (en) *	1990-12-13	1993-06-08	Tenax Corporation	Inhalation actuated dispensing apparatus
NZ241034A (en) *	1990-12-17	1995-03-28	Minnesota Mining & Mfg	Inhaler device with a dosage control that deactivates an aerosol generator after predetermined time or dosage
US5099833A (en) *	1991-02-19	1992-03-31	Baxter International Inc.	High efficiency nebulizer having a flexible reservoir
AU1442592A (en) *	1991-02-20	1992-09-15	Nova Pharmaceutical Corporation	Controlled release microparticulate delivery system for proteins
US5186164A (en) *	1991-03-15	1993-02-16	Puthalath Raghuprasad	Mist inhaler
DE59107894D1 (de) *	1991-03-21	1996-07-11	Ritzau Pari Werk Gmbh Paul	Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
GB9106648D0 (en) *	1991-03-28	1991-05-15	Rhone Poulenc Rorer Ltd	New inhaler
US5993805A (en)	1991-04-10	1999-11-30	Quadrant Healthcare (Uk) Limited	Spray-dried microparticles and their use as therapeutic vehicles
GB9107628D0 (en) *	1991-04-10	1991-05-29	Moonbrook Limited	Preparation of diagnostic agents
DE4193534T1 (de) *	1991-04-15	1997-07-24	Leiras Oy	Vorrichtung zum Abmessen einer Dosis pulverförmigen Arzneimittels für die Inhalation
DE4117751A1 (de)	1991-05-30	1992-12-03	Bayer Ag	Verfahren zur isolierung von polycarbonaten
WO1993000951A1 (en) *	1991-07-02	1993-01-21	Inhale, Inc.	Method and device for delivering aerosolized medicaments
GB9116610D0 (en)	1991-08-01	1991-09-18	Danbiosyst Uk	Preparation of microparticles
US5161524A (en) *	1991-08-02	1992-11-10	Glaxo Inc.	Dosage inhalator with air flow velocity regulating means
US5269980A (en)	1991-08-05	1993-12-14	Northeastern University	Production of polymer particles in powder form using an atomization technique
US6123924A (en)	1991-09-25	2000-09-26	Fisons Plc	Pressurized aerosol inhalation compositions
ATE154241T1 (de)	1991-10-01	1997-06-15	Takeda Chemical Industries Ltd	Mikropartikeln-zusammenfassung zur verlängerten freigabe und herstellung derselbe
US5733731A (en)	1991-10-16	1998-03-31	Affymax Technologies N.V.	Peptide library and screening method
GB9123953D0 (en)	1991-11-12	1992-01-02	Minnesota Mining & Mfg	Inhalation device
US5206219A (en) *	1991-11-25	1993-04-27	Applied Analytical Industries, Inc.	Oral compositions of proteinaceous medicaments
US5320094A (en) *	1992-01-10	1994-06-14	The Johns Hopkins University	Method of administering insulin
EP0621774B1 (en) *	1992-01-21	1996-12-18	Sri International	Improved process for preparing micronized polypeptide drugs
US5639441A (en)	1992-03-06	1997-06-17	Board Of Regents Of University Of Colorado	Methods for fine particle formation
ES2177544T3 (es) *	1992-06-12	2002-12-16	Teijin Ltd	Polvo ultrafinno para inhalar y metodo para su preparacion.
US5376359A (en) *	1992-07-07	1994-12-27	Glaxo, Inc.	Method of stabilizing aerosol formulations
US6582728B1 (en) *	1992-07-08	2003-06-24	Inhale Therapeutic Systems, Inc.	Spray drying of macromolecules to produce inhaleable dry powders
AU4198793A (en)	1992-07-24	1994-01-27	Takeda Chemical Industries Ltd.	Microparticle preparation and production thereof
ES2179831T3 (es)	1992-09-29	2003-02-01	Inhale Therapeutic Syst	Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana.
GB9221329D0 (en)	1992-10-10	1992-11-25	Delta Biotechnology Ltd	Preparation of further diagnostic agents
CA2147260C (en)	1992-10-19	1999-04-13	Mark Bernard Mecikalski	Dry powder inhaler
HU221308B1 (en)	1992-10-26	2002-09-28	Sanol Arznei Schwarz Gmbh	Process for producing microcapsules
GB9226474D0 (en)	1992-12-18	1993-02-10	Ici Plc	Production of particulate materials
US5364838A (en) *	1993-01-29	1994-11-15	Miris Medical Corporation	Method of administration of insulin
US5354934A (en) *	1993-02-04	1994-10-11	Amgen Inc.	Pulmonary administration of erythropoietin
IL105658A (en)	1993-05-11	1995-10-31	Ultrasonic Dryer Ltd	Spray drying system
TW402506B (en) *	1993-06-24	2000-08-21	Astra Ab	Therapeutic preparation for inhalation
US5506203C1 (en) *	1993-06-24	2001-02-06	Astra Ab	Systemic administration of a therapeutic preparation
IS1796B (is) *	1993-06-24	2001-12-31	Ab Astra	Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5595761A (en)	1994-01-27	1997-01-21	The Board Of Regents Of The University Of Oklahoma	Particulate support matrix for making a rapidly dissolving tablet
US5635210A (en)	1994-02-03	1997-06-03	The Board Of Regents Of The University Of Oklahoma	Method of making a rapidly dissolving tablet
CA2184582C (en) *	1994-03-04	2001-12-25	Hak-Kim Chan	Pharmaceutically acceptable dnase formulation
NZ281112A (en)	1994-03-07	1998-04-27	Inhale Therapeutic Syst	Powdered insulin delivered as an aerosol
US6051256A (en)	1994-03-07	2000-04-18	Inhale Therapeutic Systems	Dispersible macromolecule compositions and methods for their preparation and use
ES2245780T3 (es) *	1994-05-18	2006-01-16	Nektar Therapeutics	Metodos y composiciones para la formulacion de interferones como un polvo seco.
US5580856A (en) *	1994-07-15	1996-12-03	Prestrelski; Steven J.	Formulation of a reconstituted protein, and method and kit for the production thereof
US6290991B1 (en)	1994-12-02	2001-09-18	Quandrant Holdings Cambridge Limited	Solid dose delivery vehicle and methods of making same
PL319600A1 (en) *	1994-09-29	1997-08-18	Andaris Ltd	Spray-dried microparticles as therapeutic carriers
US6117455A (en)	1994-09-30	2000-09-12	Takeda Chemical Industries, Ltd.	Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
GB9423419D0 (en)	1994-11-19	1995-01-11	Andaris Ltd	Preparation of hollow microcapsules
US5970974A (en)	1995-03-14	1999-10-26	Siemens Aktiengesellschaft	Dosating unit for an ultrasonic atomizer device
US5922253A (en)	1995-05-18	1999-07-13	Alkermes Controlled Therapeutics, Inc.	Production scale method of forming microparticles
US5607697A (en)	1995-06-07	1997-03-04	Cima Labs, Incorporated	Taste masking microparticles for oral dosage forms
US5667806A (en) *	1995-06-07	1997-09-16	Emisphere Technologies, Inc.	Spray drying method and apparatus
GB9515182D0 (en)	1995-07-24	1995-09-20	Co Ordinated Drug Dev	Improvements in and relating to powders for use in dry powder inhalers
US5687905A (en)	1995-09-05	1997-11-18	Tsai; Shirley Cheng	Ultrasound-modulated two-fluid atomization
DE19536902A1 (de)	1995-10-04	1997-04-10	Boehringer Ingelheim Int	Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
GB9607035D0 (en)	1996-04-03	1996-06-05	Andaris Ltd	Spray-dried microparticles as therapeutic vehicles
DE19617487A1 (de)	1996-05-02	1997-11-06	Merck Patent Gmbh	Geschmacksverbesserung von Arzneimittelwirkstoffen
US5874064A (en)	1996-05-24	1999-02-23	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
US5985309A (en)	1996-05-24	1999-11-16	Massachusetts Institute Of Technology	Preparation of particles for inhalation
US5855913A (en)	1997-01-16	1999-01-05	Massachusetts Instite Of Technology	Particles incorporating surfactants for pulmonary drug delivery
US6503480B1 (en)	1997-05-23	2003-01-07	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
TW305239U (en)	1996-06-28	1997-05-11	Ind Tech Res Inst	Generating apparatus of gaseous glue capable of distributing particles with narrow diameters
JP3585654B2 (ja)	1996-07-11	2004-11-04	株式会社パウダリングジャパン	２段乾燥式スプレードライヤー装置
US6017310A (en)	1996-09-07	2000-01-25	Andaris Limited	Use of hollow microcapsules
US20030203036A1 (en)	2000-03-17	2003-10-30	Gordon Marc S.	Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US6077543A (en)	1996-12-31	2000-06-20	Inhale Therapeutic Systems	Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US6383810B2 (en)	1997-02-14	2002-05-07	Invitrogen Corporation	Dry powder cells and cell culture reagents and methods of production thereof
US6051257A (en) *	1997-02-24	2000-04-18	Superior Micropowders, Llc	Powder batch of pharmaceutically-active particles and methods for making same
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
GB9727102D0 (en)	1997-12-22	1998-02-25	Andaris Ltd	Microparticles and their therapeutic use
GB9825883D0 (en)	1998-11-27	1999-01-20	Aea Technology Plc	Formation of monodisperse particles
US6223455B1 (en)	1999-05-03	2001-05-01	Acusphere, Inc.	Spray drying apparatus and methods of use
US20020081266A1 (en)	1999-08-20	2002-06-27	Norton Healthcare Ltd.	Spray dried powders for pulmonary or nasal administration
NL1013893C2 (nl)	1999-12-20	2001-06-21	Stork Friesland Bv	Inrichting voor het verstuiven van een vloeibaar product, een daarvan voorziene sproeidroog- en conditionerings-inrichting alsmede een werkwijze voor het conditioneren van een vloeibaar product.
US6656492B2 (en)	2000-06-30	2003-12-02	Yamanouchi Pharmaceutical Co., Ltd.	Quick disintegrating tablet in buccal cavity and manufacturing method thereof
US6455028B1 (en)	2001-04-23	2002-09-24	Pharmascience	Ipratropium formulation for pulmonary inhalation
WO2003037303A1 (en)	2001-11-01	2003-05-08	Nektar Therapeutics	Spray drying methods and compositions thereof

1996
- 1996-05-08 US US08/644,681 patent/US6051256A/en not_active Expired - Lifetime
1997
- 1997-05-07 GE GEAP19974599A patent/GEP20012345B/en unknown
- 1997-05-07 IL IL12675497A patent/IL126754A/xx not_active IP Right Cessation
- 1997-05-07 SK SK1525-98A patent/SK285400B6/sk not_active IP Right Cessation
- 1997-05-07 CZ CZ19983599A patent/CZ295644B6/cs not_active IP Right Cessation
- 1997-05-07 CN CNB971944709A patent/CN1138531C/zh not_active Expired - Fee Related
- 1997-05-07 WO PCT/US1997/007779 patent/WO1997041833A1/en not_active Ceased
- 1997-05-07 BR BR9709057A patent/BR9709057A/pt not_active Application Discontinuation
- 1997-05-07 YU YU50198A patent/YU49206B/sh unknown
- 1997-05-07 PL PL97329870A patent/PL190732B1/pl not_active IP Right Cessation
- 1997-05-07 EE EE9800376A patent/EE03591B1/xx not_active IP Right Cessation
- 1997-05-07 CA CA002253393A patent/CA2253393C/en not_active Expired - Fee Related
- 1997-05-07 EP EP97926420A patent/EP0948317A4/en not_active Withdrawn
- 1997-05-07 SI SI9720031A patent/SI9720031A/sl not_active IP Right Cessation
- 1997-05-07 NZ NZ332480A patent/NZ332480A/xx unknown
- 1997-05-07 RO RO98-01547A patent/RO118523B1/ro unknown
- 1997-05-07 EA EA199800983A patent/EA000956B1/ru not_active IP Right Cessation
- 1997-05-07 JP JP09540191A patent/JP2000510471A/ja not_active Withdrawn
- 1997-05-07 AU AU31190/97A patent/AU730059B2/en not_active Ceased
- 1997-05-07 AP APAP/P/1998/001369A patent/AP987A/en active
- 1997-05-07 TR TR1998/02247T patent/TR199802247T2/xx unknown
- 1997-06-14 TW TW086108261A patent/TW550089B/zh not_active IP Right Cessation
- 1997-07-05 UA UA98126441A patent/UA65538C2/uk unknown
1998
- 1998-10-26 IS IS4879A patent/IS4879A/is unknown
- 1998-10-28 BG BG102875A patent/BG64113B1/bg unknown
- 1998-11-05 OA OA9800212A patent/OA10914A/en unknown
- 1998-11-06 NO NO985196A patent/NO985196L/no not_active Application Discontinuation
- 1998-11-09 LT LT98-157A patent/LT4553B/lt not_active IP Right Cessation
- 1998-11-30 LV LVP-98-273A patent/LV12231B/en unknown
2000
- 2000-02-04 US US09/498,397 patent/US6423344B1/en not_active Expired - Lifetime
2001
- 2001-11-09 US US10/007,868 patent/US6592904B2/en not_active Expired - Fee Related
2003
- 2003-03-31 US US10/403,482 patent/US7138141B2/en not_active Expired - Fee Related
2006
- 2006-09-28 US US11/536,348 patent/US8173168B2/en not_active Expired - Fee Related
2009
- 2009-04-15 JP JP2009099209A patent/JP2009191071A/ja active Pending

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4837892B2 (ja) *	2001-11-01	2011-12-14	ネクターセラピューティクス	粉末バッチを製造する方法
JP2006512102A (ja) *	2002-04-11	2006-04-13	メディミューン・ヴァクシンズ・インコーポレーテッド	噴霧乾燥による生物活性材料の防腐
JP2011006444A (ja) *	2002-12-17	2011-01-13	Medimmune Llc	生物活性材料の高圧噴霧乾燥
JP4808970B2 (ja) *	2002-12-30	2011-11-02	ネクターセラピューティクス	噴霧乾燥システム
JP2011245314A (ja) *	2002-12-30	2011-12-08	Nektar Therapeutics	液滴を形成するための噴霧器、噴霧乾燥システム及び液滴形成装置
JP2007522246A (ja) *	2004-02-12	2007-08-09	ネクターセラピューティクス	インターロイキン−１３拮抗剤粉末剤、スプレードライ粒子、及び方法
JP2007536313A (ja) *	2004-05-10	2007-12-13	ベーリンガーインゲルハイムファルマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト	少なくとも１種の１，４ｏ−結合型サッカロース誘導体を含有する噴霧乾燥粉末及びその製造方法
JP2007536315A (ja) *	2004-05-10	2007-12-13	ベーリンガーインゲルハイムファルマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト	新規なオリゴ糖混合物を含有する粉末及びその製造方法

Also Published As

Publication number	Publication date
EA199800983A1 (ru)	1999-04-29
EE03591B1 (et)	2002-02-15
JP2009191071A (ja)	2009-08-27
EP0948317A1 (en)	1999-10-13
EE9800376A (et)	1999-04-15
BR9709057A (pt)	1999-08-03
US6592904B2 (en)	2003-07-15
GEP20012345B (en)	2001-01-25
UA65538C2 (en)	2004-04-15
US20020122827A1 (en)	2002-09-05
IL126754A (en)	2003-06-24
US6423344B1 (en)	2002-07-23
SK152598A3 (en)	1999-04-13
CA2253393C (en)	2007-10-09
IL126754A0 (en)	1999-08-17
NZ332480A (en)	2000-01-28
BG64113B1 (bg)	2004-01-30
EA000956B1 (ru)	2000-08-28
SK285400B6 (sk)	2007-01-04
YU50198A (sh)	2000-12-28
RO118523B1 (ro)	2003-06-30
PL190732B1 (pl)	2005-12-30
US20030215514A1 (en)	2003-11-20
PL329870A1 (en)	1999-04-12
CZ295644B6 (cs)	2005-09-14
LT4553B (lt)	1999-10-25
AU3119097A (en)	1997-11-26
OA10914A (en)	2001-10-26
AU730059B2 (en)	2001-02-22
YU49206B (sh)	2004-09-03
CA2253393A1 (en)	1997-11-13
NO985196L (no)	1999-01-06
EP0948317A4 (en)	2006-02-01
BG102875A (en)	1999-05-31
CZ359998A3 (cs)	1999-03-17
US8173168B2 (en)	2012-05-08
LV12231A (lv)	1999-03-20
LT98157A (en)	1999-05-25
HK1020319A1 (en)	2000-04-14
IS4879A (is)	1998-10-26
US20070020199A1 (en)	2007-01-25
CN1138531C (zh)	2004-02-18
SI9720031A (sl)	1999-02-28
TR199802247T2 (xx)	2001-11-21
NO985196D0 (no)	1998-11-06
AP9801369A0 (en)	1998-12-31
WO1997041833A1 (en)	1997-11-13
US6051256A (en)	2000-04-18
TW550089B (en)	2003-09-01
LV12231B (en)	1999-10-20
AP987A (en)	2001-08-01
CN1218394A (zh)	1999-06-02
US7138141B2 (en)	2006-11-21

Legal Events

Date	Code	Title	Description
2004-04-30	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040409
2004-04-30	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040409
2008-03-18	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080318
2008-07-10	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080617
2008-07-28	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080728
2008-09-25	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080905
2008-12-16	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081216
2009-03-17	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090316
2009-07-01	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090702
2009-07-15	A761	Written withdrawal of application	Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20090714

Publication	Publication Date	Title
JP2000510471A (ja)	2000-08-15	分散性高分子組成物並びにそれらの調製及び使用のための方法
WO1997041833A9 (en)	1998-02-12	Dispersible macromolecule compositions and methods for their preparation and use
Johnson	1997	Preparation of peptide and protein powders for inhalation
JP4378057B2 (ja)	2009-12-02	流動抵抗調節されたエアロゾル化活性薬剤送達
US6509006B1 (en)	2003-01-21	Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
EP0866726B1 (en)	2004-03-03	Pulmonary administration of dry powder alpha 1-antitrypsin
KR100951750B1 (ko)	2010-04-09	분무 건조 방법 및 그 조성물
JPH11503731A (ja)	1999-03-30	エアゾール化医薬の肺への送達
CA2466982A1 (en)	2003-05-30	Pharmaceutical compositions in particulate form
JP2001507700A (ja)	2001-06-12	疎水性エアゾール薬剤
JP2009106790A (ja)	2009-05-21	乾燥粉末を調整するための噴霧乾燥法
KR100473212B1 (ko)	2005-07-21	분산성고분자조성물과이의제조방법및용도
MXPA98009272A (en)	1999-10-14	Compositions of dispersible macromolecules and methods for their preparation and
HK1020319B (en)	2004-12-17	Dispersible macromolecule compositions and methods for their preparation and use
CN118845721A (zh)	2024-10-29	可吸入团聚纳米颗粒干粉药物组合物、及其制备方法和用途
Powder	0	Laboratory Scale Spray Drying of Lactose: A Review